Take your body seriously and if you have complaints, go to the doctor and get yourself checked.’
Merel Hennink of LuCE Member Longkanker Nederland, stresses the importance of knowing that anyone with lungs can get lung cancer and that if you have symptoms, get yourself checked.

‘As a healthcare professional, one of the greatest objectives we have is that every patient and family going through the diagnosis of lung cancer has a key worker: someone they can reach out to and contact should they have any concerns or questions.’
Lavinia Magee, LuCE Board Member from Lung Cancer Nursing UK, talks about the importance of support for those going through lung cancer treatment or impacted by it.

‘People who are diagnosed with lung cancer are diagnosed too late. The average is 70% or 80% of people who are declared with stage 4. I think we should have a policy of early screening to get rid of this.’
Alexandre Brutti, LuCE Board Member from Mon Réseau Cancer du Poumon, stresses the importance of early screening.
Thank you, Alexandre.

Yvonne Diaz of LuCE member, Oncogene Cancer Research, says that the most important thing to know is that anyone can get lung cancer.
Because of this, it is essential to be educated about the signs and to get checked if you are in doubt.
Knowing the type of lung cancer you have is important as it can allow for personalised treatment options, target therapies and improved prognosis.
Thank you, Yvonne, for these brilliant insights.

LuCE member, Diego Villalón of Fundacion Más Que Ideas talks about what he believes are the key messages about lung cancer: prevention is crucial in lung cancer and we need to raise awareness that anyone can be impacted by lung cancer.

This webinar explores the complexities of evidence-based advocacy through the lens of lung cancer screening. Using a real-world case study, we will delve into the ethical considerations and health data challenges that arise in screening programmes, focusing on how patient organisations and advocates can navigate these issues to ensure responsible and effective advocacy

This session offers valuable insights into how advocacy can shape health policies, particularly in the context of lung cancer screening. Attendees will leave with a deeper understanding of:

· The ethical dimensions of health data use.
· Practical strategies for driving evidence-based advocacy.
· How to apply these learnings to ongoing advocacy efforts in the lung cancer community.

The session was given on 4th November 2024 by:
· Lauren Michiels, PhD, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
· Dr. Teodora Lalova-Spinks, Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Belgium

The primary aim of this session is to provide attendees with the latest updates on developments and research trends in lung cancer, enhancing their understanding of both current and emerging therapies.

The session was given by Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif.

The session was held on 4th July 2024.

The primary aim of this session was to explore how real-world data can be utilized to enhance clinical practice and policy-making in lung cancer, emphasizing the importance of data in improving patient outcomes.

The session was be given by Eleni Kokkotou, MD, MSc, PhDc, Pulmonologist and TB Specialist at the Oncology Unit, 3rd Department of Internal Medicine, "Sotiria" General Hospital, University of Athens

The session was held on 26th June 2024.